Stockscreener 앱 받기
18.48
1.96%
-0.37
시간 외 거래:
18.50
0.02
+0.11%
전일 마감가:
$18.85
열려 있는:
$18.97
하루 거래량:
2.09M
Relative Volume:
3.06
시가총액:
$1.01B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.54%
1개월 성능:
+23.94%
6개월 성능:
+59.72%
1년 성능:
+2.41%
1일 변동 폭
$18.32
$19.58
1주일 범위
$18.08
$19.68
52주 변동 폭
$7.80
$19.75
Bicara Therapeutics Inc Stock (BCAX) Company Profile
명칭
Bicara Therapeutics Inc
전화
617-468-4219
주소
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.48 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2025-05-23 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 개시 | Wells Fargo | Underweight |
| 2025-02-06 | 개시 | Wedbush | Outperform |
| 2024-12-06 | 개시 | H.C. Wainwright | Buy |
| 2024-11-05 | 개시 | Rodman & Renshaw | Buy |
| 2024-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 개시 | Morgan Stanley | Overweight |
| 2024-10-08 | 개시 | Stifel | Buy |
| 2024-10-08 | 개시 | TD Cowen | Buy |
모두보기
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Australia
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView — Track All Markets
Bicara Therapeutics reports promising phase 1b data - MSN
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort - GlobeNewswire
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Australia
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewswire
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com
[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa
Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Bicara Therapeutics Executives Engage in Stock Sales - TradingView
Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha
Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - setenews.com
CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 9.5%Still a Buy? - MarketBeat
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc (BCAX) 재무 분석
Bicara Therapeutics Inc (BCAX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Bicara Therapeutics Inc 주식 (BCAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Option Exercise |
3.79 |
605 |
2,293 |
145,960 |
| Hyep Ivan | Chief Financial Officer |
Nov 24 '25 |
Sale |
18.55 |
17,795 |
330,094 |
145,355 |
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Sale |
18.15 |
605 |
10,981 |
145,355 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Option Exercise |
3.79 |
8,000 |
30,318 |
206,141 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Sale |
18.05 |
12,500 |
225,588 |
193,641 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
41,163 |
156,000 |
351,055 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Sale |
18.86 |
41,163 |
776,429 |
309,892 |
| Raben David | Chief Medical Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,997 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,091 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Sale |
18.84 |
5,500 |
103,633 |
35,497 |
1.08%
0.91%
자본화:
|
볼륨(24시간):